How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,605 results for

Murphy Sign

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Genitourinary syndrome of menopause

estrogen – Vulvovaginal atrophy. G enitourinary syndrome of menopause (GSM) describes the symptoms and signs resulting from the effect of estrogen deficiency on the female genitourinary tract. Symptoms associated with GSM are highly prevalent, affecting approximately 27% to 84% of postmenopausal women. 1-4 In one report of more than Received May 14, 2020; revised and accepted May 14, 2020. This position statement was developed by The North American Meno- pause Society (NAMS) consisting (...) Genitourinarysyndromeofmenopause describes the symp- toms and signs resulting from the effect of estrogen deficiency on the female genitourinary tract, including the vagina, labia, urethra, and bladder. 12 This syndrome includes genital symp- toms of dryness, burning, and irritation; urinary symptoms and conditions of dysuria, urgency, and recurrent urinary tract infections (UTIs); and sexual symptoms of pain and dryness. Physical changes and signs are varied. Women may experi- ence some or all of the symptoms and signs

2020 The North American Menopause Society

83. Preterm labour and birth

observation or investigation indicated or • Other maternal or fetal concerns Admit • Analgesia if required • Clinical surveillance • Fetal monitoring/continuous CTG • TVCL if available • Consult as required • Plan care Yes No Discharge • Provide information re: signs and symptoms and returning for care • Arrange follow-up as indicated CTG: Cardiotocograph, fFN: Fetal fibronectin, FHR: Fetal heart rate, g: grams, GBS: Group B Streptococcus, IV: Intravenous, kg: kilogram, MC&S: microscopy, culture (...) intrapartum antibiotic prophylaxis for prevention of Early onset Group B streptococcal disease irrespective of GBS status or membrane status • Refer to Queensland Clinical Guideline Early onset Group B Streptococcus disease 63 Signs of chorioamnionitis (Intact or ruptured membranes)* • Signs of chorioamnionitis include: o Maternal fever greater than 38°C (present in 95–100% of cases) 64 o Maternal tachycardia greater than 100 beats per minute (bpm) (present in 50–80% of cases) 64 o Fetal tachycardia

2020 Queensland Health

85. Endovascular Aortic Repair of Aneurysms Involving the Renal-Mesenteric Arteries (FEVAR) Full Text available with Trip Pro

, compromisse of side branches Coexisting pathology All pertinent pathology should be listed The primary pathology entity should be designated Standard classifications of type, etiology, time course and clinopathological manifestations All types of pathology should be accompanied by hemodynamic status at presentation, repair: stable, unstable, vital signs, associated cardiac arrest Table III A summary of Familial Thoracic Aortic Aneurysm and Dissection (FTAAD) genes, including year of discovery, number

2020 Society for Vascular Surgery

86. Thoracic Endovascular Aneurysm Repair TEVAR Full Text available with Trip Pro

(COPD) was noted in 80% of the subgroup with rupture. Crawford E.S. DeNatale R.W. Thoracoabdominal aortic aneurysm: observations regarding the natural course of the disease. Journal of vascular surgery. 1986; 3 : 578-582 Similar studies in patients with small infrarenal AAA have confirmed COPD as a significant risk factor for rupture. Cronenwett J. Murphy T. Zelenock G. Whitehouse Jr., W. Lindenauer S. Graham L.M. et al. Actuarial analysis of variables associated with rupture of small abdominal (...) of vascular surgery. 1986; 3 : 578-582 , Cronenwett J. Murphy T. Zelenock G. Whitehouse Jr., W. Lindenauer S. Graham L.M. et al. Actuarial analysis of variables associated with rupture of small abdominal aortic aneurysms. Surgery. 1985; 98 : 472-483 , Cambria R.A. Gloviczki P. Stanson A.W. Cherry K.J. Bower T.C. Hallett J.W. et al. Outcome and expansion rate of 57 thoracoabdominal aortic aneurysms managed nonoperatively. The American journal of surgery. 1995; 170 : 213-217 , Griepp R.B. Ergin M.A. Galla

2020 Society for Vascular Surgery

87. Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper

transmission rates were historically higher in solid organ transplantation recipients (24), the recent availability of DAAs has decreased infections in solid-organ transplant recipients (25). In a clinical trial, recipients of heart and lung transplants from hepatic C viremic donors (median viral load: 890,000 IU/ml) received preemptive therapy with sofos- buvir-velpatasvir within a few hours after transplantation, with undetectable HCV viral loads 6 months posttransplant (25). CLINICAL SIGNS AND SYMPTOMS (...) Virol 2012;157:329–32. 20. Carney K, Dhalla S, Aytaman A, et al. Association of tattooing and hepatitis C virus infection: a multicenter case-control study. Hepatol- ogy 2013;57:2117–23. Leung et al JPGN Volume 71, Number 3, September 2020 414 www.jpgn.org Copyright © ESPGHAN and NASPGHAN. All rights reserved. 21. TohmeRA,HolmbergSD.Issexualcontactamajormodeofhepatitis C virus transmission? Hepatology 2010;52:1497–505. 22. Terrault NA, Dodge JL, Murphy EL, et al. Sexual transmission of hepatitisC

2020 North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

88. Guidelines for diagnosing and managing disseminated histoplasmosis among people living with HIV

and maintenance of antifungal treatment regimens for disseminated histoplasmosis among people living with HIV Disseminated histoplasmosis classification definitions • Severe or moderately severe histoplasmosis is defined as the presence of at least one sign or symptom involving vital organs: respiratory or circulatory failure, neurological signs, renal failure, coagulation anomalies and a general alteration of the WHO performance status greater than 2, in which the person is confined to a bed or chair more (...) than half of the waking hours and only capable of limited self-care. • Mild to moderate histoplasmosis is defined as signs and symptoms that do not include the above features defining severe or moderately severe histoplasmosis. 2.1 Induction therapy 2.1.1 Treating severe or moderately severe histoplasmosis among people living with HIV: liposomal amphotericin B, 3.0 mg/kg, for two weeks is recommended (conditional recommendation; very-low-certainty evidence). In settings where liposomal amphotericin

2020 World Health Organisation HIV Guidelines

89. Microhematuria: AUA/SUFU Guideline

into the toilet in order to collect the midstream void. If a significant number of squamous cells are present in the sample, then contamination is possible and a repeat specimen collection or catheterization should be considered. Providing basic instructions to patients on proper sample collection, verbally, in writing, or on posted signs, could minimize contaminated or faulty samples. Male patients: Midstream voided specimens are adequate unless the patient is unable to void. The specimen can be collected (...) perform a probative history and physical examination. As gynecological bleeding may be confused with MH, a menstrual and gynecological history should be obtained, and a catheterized UA may be helpful to confirm MH. A more extensive gynecologic history and pelvic examination should be performed by a clinician capable of assessing for gynecologic conditions when indicated by the gynecologic history. Symptoms and signs of UTI, such as fever and dysuria, should be elicited. Patients should be asked about

2020 Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction

91. GPP The prevention of central nervous system relapse in diffuse large B?cell lymphoma Full Text available with Trip Pro

nervous system involvement following diagnosis of non‐Hodgkin's lymphoma: a risk model . Ann Oncol . 2002 ; 13 : 1099 – 107 . 12 Tomita N , Yokoyama M , Yamamoto W , Watanabe R , Shimazu Y , Masaki Y , et al. The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxis . Leukemia & Lymphoma . 2018 ; 59 : 97 – 104 . 13 van Besien K , Ha CS , Murphy S , McLaughlin P , Rodriguez A , Amin K , et al. Risk factors, treatment, and outcome (...) below. Email or Customer ID Please check your email for instructions on resetting your password. If you do not receive an email within 10 minutes, your email address may not be registered, and you may need to create a new Wiley Online Library account. Request Username Can't sign in? Forgot your username? Enter your email address below and we will send you your username Email or Customer ID If the address matches an existing account you will receive an email with instructions to retrieve your

2020 British Committee for Standards in Haematology

93. Microhematuria: AUA/SUFU Guideline

of voided urine into the toilet in order to collect the midstream void. If a significant number of squamous cells are present in the sample, then contamination is possible and a repeat specimen collection or catheterization should be considered. Providing basic instructions to patients on proper sample collection, verbally, in writing, or on posted signs, could minimize contaminated or faulty samples. Male patients: Midstream voided specimens are adequate unless the patient is unable to void (...) should be obtained, and a catheterized UA may be helpful to confirm MH. A more extensive gynecologic history and pelvic examination should be performed by a clinician capable of assessing for gynecologic conditions when indicated by the gynecologic history. Symptoms and signs of UTI, such as fever and dysuria, should be elicited. Patients should be asked about the presence of flank pain, which may herald a urinary tract stone, and obstructive urinary symptoms, which may signal the presence

2020 American Urological Association

94. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Joint Guideline

of outcomes in each intervention group). Discrepancies between calculated and reported results were noted when present. For diagnostic accuracy studies, the following information was abstracted: setting, screening test or tests, method of data collection, reference standard, inclusion criteria, population characteristics (including age, sex, race, smoking status, signs or symptoms, and prior bladder cancer stage or grade), proportion of individuals with bladder cancer, bladder cancer stage and grade (...) , evaluation, and follow-up of patients with asymptomatic microhematuria (AMH), the rate of urinary tract malignancy in AMH is approximately 2.6%. 29 Irritative voiding symptoms (e.g., frequency, urgency, dysuria) may also be associated with CIS in patients with no sign of urinary tract infection. Physical exam rarely reveals significant findings in patients with NMIBC. However, a bimanual exam may be performed under anesthesia at the time of transurethral resection of bladder tumor (TURBT) and should

2020 American Urological Association

95. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline

). Further, neuroendocrine tumors and small cell variants were considered outside the scope of this guideline. Biochemical recurrence (“rising PSA state”) without metastatic disease after exhaustion of local treatment options After local therapy including surgery or radiation, the first sign of recurrence is typically a rising PSA in the absence of visible metastases. This is assuming also that all forms of local therapy (e.g., salvage radiotherapy after radical prostatectomy, or salvage prostatectomy (...) ) with a predetermined statistical plan. Institutional Review Boards approve all clinical trials and patient consent forms, and all patients must sign consent for trial participation. In appropriate patients, clinical trial options should be considered, and trial options should be discussed with patients as part of the shared decision-making process. Clinical trials are listed by diagnosis and stage on the Clinicaltrials.gov website. Early Evaluation and Counseling Guideline Statement 1 1. In patients with suspicion

2020 American Urological Association

96. Management of Bleeding in Patients on Oral Anticoagulants

the initial assessment, a focused history and physical examination, with collection of vital signs and laboratory evaluation, should be obtained, with the aim of determining time of onset, location, severity of bleeding, and whether bleeding is ongoing. The assessment of hemodynamic instability should be done promptly and repeated frequently. Patients with major bleeds, with or without hemodynamic instability, require close monitoring, ideally in the acute or critical care setting. Additional (...) , it can result in hemodynamic compromise. A list of critical bleeding locations can be found in Table 1. 5.2.2. Hemodynamic Instability An increased heart rate may be the ?rst sign of hemody- namic instability due to blood loss. Furthermore, a sys- tolic blood pressure 40 mm Hg (13), or orthostatic blood pressure changes (systolic blood pressure drop $20 mm Hg or diastolic blood pressure drop$10 mm Hg upon standing) can indicate hemodynamic instability. Howev- er, noninvasively measured blood pressure

2020 American College of Cardiology

97. NCCP advice on the management of patients undergoing radiation oncology treatment, in response to the current novel coronavirus (COVID-19) outbreak

protocol including deferral/ interruption should be discussed with patient. Planning meetings are essential in this phase of the COVID-19 outbreak. If a planning meeting is not possible sign off of the protocol should be in consultation with another consultant. 4 Communication with radiation oncology patients 1. Communicate with patients and support their mental wellbeing, signposting to charities and support groups where available, to help alleviate any anxiety and fear they may have about COVID-19. 2 (...) Cormac Small - Consultant Radiation Oncologist Dr Carol McGibney - Consultant Radiation Oncologist Dr Clare Faul - Consultant Radiation Oncologist Dr Eve O’Toole - Guideline Lead, NCCP, Ms Ruth Ryan - Programme Manager, NCCP Ms Louise Murphy - Research Officer, NCCP

2020 Health Service Executive (Ireland) - Clinical Guidelines

98. Covid-19: Guidance review for emergency medical dispatch centres

and risk factors (e.g., history of travel to affected areas), based on current case definition. Patients who meet the appropriate criteria should be evaluated and transported as a person under investigation (PUI). Where the PUI is experiencing Review of guidance for the operation of emergency medical dispatch centres Health Information and Quality Authority Page 12 of 82 COVID-19 signs and symptoms, this needs to be communicated to pre-hospital first responders and to the receiving hospital. Practice (...) be considered and include the following: ? watch for atypical signs in staff behaviours and address as soon as possible. ? communicate with staff regarding new measures and provide information regarding available supports (e.g. peer support, employee assistance programme, employee wellness programme, Critical incident Stress Management (CiSM) support). ? develop formal/informal wellness plans. ? encourage EMS personnel to create structure at home to help create certainty and normalise the home. ? ensure

2020 Health Information and Quality Authority

99. Nutrition screening and use of oral nutrition support for adults in the acute care setting

and Language Therapist, Cork University Hospital, IASLT Pharmacy personnel Mr Damodar Solanki Chief II Pharmacist, Beaumont Hospital Non-clinical key personnel (alphabetical order) Ms Wendy McMahon Catering Production Manager, Mater Misericordiae University Hospital Mr Paul J. Murphy Information Specialist, RCSI Library Dr James O’Mahony Health Economist, Trinity College Dublin Ms Niamh Rice Director of Irish Society for Clinical Nutrition and Metabolism (IrSPEN) Consulting to the GDG - Information (...) successfully submitted the guideline proposal for NCEC prioritisation, with assistance from Ms Rosarie Lynch of CEU. • Funding from HSE Acute Operations and Strategy and Planning, and Strategic Planning and Transformation. • Dr Barbara Clyne, Mr Barrie Tyner and Ms Michelle O’Neill and their team from the Health Research Board-Collaboration in Ireland for Clinical Effectiveness Reviews (HRB-CICER), carried out the systematic reviews. • Mr Paul J. Murphy of the Royal College of Surgeons in Ireland (RCSI

2020 National Clinical Guidelines (Ireland)

100. Management of Adult Overweight and Obesity (OBE)

Jain Research & Consulting Anjali Jain, MD Sigma Health Consulting Frances Murphy, MD, MPH Duty First Consulting Rachel Piccolino, BA Megan McGovern, BA a Additional contributor contact information is available in Appendix E. VA/DoD Clinical Practice Guideline for the Management of Adult Overweight and Obesity July 2020 Page 18 of 147 V. Algorithm This CPG includes an algorithm that is designed to facilitate understanding of the clinical pathways and decision-making processes used in managing

2020 VA/DoD Clinical Practice Guidelines

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>